Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
Measuring cellular poly ADP-ribosylation can unlock new anticancer strategies and approaches. ADP-ribosylation, the attachment of ADP-ribose to proteins, is a common eukaryotic post-translational ...
Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a demethyltransferase 1 (DNMT1) inhibitor to tumors in mouse cancer models. 1 ...
BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...
Hosted on MSN1mon
Olaparib could be a safe, effective maintenance therapy in some ovarian cancer patientsOvarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...
These drugs stop a protein known as poly-ADP ribose polymerase (PARP) from repairing cancer cells, so the cells die. They're given to women who have a mutation in the BRCA gene and HER2-negative ...
Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...
Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...
Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) announced that its board has authorized a share repurchase plan on Monday, March 3rd, RTT News reports. The company plans to buyback $5.00 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results